卵巢癌中紫杉醇耐药性研究进展

doi:10.11904/j.issn.1002-3070.2025.04.013

Abstract

Abstract: Ovarian cancer has the highest mortality among all gynecological tumors.Currently,platinum and taxanes based chemotherapy drugs are mainly used for ovarian cancer.Paclitaxel is a taxane drug,one of the most widely used chemotherapy drugs,and also a first-line chemotherapeutic drug for treating ovarian cancer.Despite its widespread use in the treatment of ovarian cancer,paclitaxel′s clinical has efficacy is hindered by the development of resistance.This article mainly discusses the mechanism and treatment strategies of paclitaxel resistance in ovarian cancer,including combination therapy,exploration of new targets,and the combination of novel carriers,providing a basis for solving the problem of paclitaxel resistance in the treatment of ovarian cancer.

Key words: Paclitaxel, Ovarian cancer, Drug resistance, Treatment strategies

CLC Number:

R737.31

WU Xiaofan, LI Lin. Research progress on paclitaxel resistance in ovarian cancer[J]. Journal of Practical Oncology, 2025, 39(4): 343-347.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2025.04.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2025/V39/I4/343

References

1 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
2 Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
3 Marupudi NI,Han JE,Li KW,et al.Paclitaxel:a review of adverse toxicities and novel delivery strategies[J].Expert Opin Drug Saf,2007,6(5):609-621.
4 Wanderley CW,Colón DF,Luiz JPM,et al.Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner[J].Cancer Res,2018,78(20):5891-5900.
5 Lau TS,Chan LKY,Man GCW,et al.Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4/IKK2/SNARE-dependent exocytosis[J].Cancer Immunol Res,2020,8(8):1099-1111.
6 Vaidyanathan A,Sawers L,Gannon AL,et al.ABCB1(MDR1)induction defines a common resistance mechanism in paclitaxel-and olaparib-resistant ovarian cancer cells[J].Br J Cancer,2016,115(4):431-441.
7 Feng Q,Li X,Sun W,et al.Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1[J].Biochem Pharmacol,2020,178:114092.
8 Lin TY,Gu SY,Lin YH,et al.Paclitaxel-resistance facilitates glycolytic metabolism via Hexokinase-2-regulated ABC and SLC transporter genes in ovarian clear cell carcinoma[J].Biomed Pharmacother,2024,180:117452.
9 Park DC,Yeo SG,Wilson MR,et al.Clusterin interacts with paclitaxel and confer paclitaxel resistance in ovarian cancer[J].Neoplasia,2008,10(9):964-972.
10 Giannakakou P,Sackett DL,Kang YK,et al.Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization[J].J Biol Chem,1997,272(27):17118-17125.
11 Mooneyham A,Iizuka Y,Yang Q,et al.UNC-45A is a novel microtubule-associated protein and regulator of paclitaxel sensitivity in ovarian cancer cells[J].Mol Cancer Res,2019,17(2):370-383.
12 Nan G,Zhao SH,Wang T,et al.CD147 supports paclitaxel resistance via interacting with RanBP1[J].Oncogene,2022,41(7):983-996.
13 Yang YI,Wang YY,Ahn JH,et al.CCL2 overexpression is associated with paclitaxel resistance in ovarian cancer cells via autocrine signaling and macrophage recruitment[J].Biomed Pharmacother,2022,153:113474.
14 Kohli A,Huang SL,Chang TC,et al.H1.0 induces paclitaxel-resistance genes expression in ovarian cancer cells by recruiting GCN5 and androgen receptor[J].Cancer Sci,2022,113(8):2616-2626.
15 Zhang SF,Wang XY,Fu ZQ,et al.TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer[J].Autophagy,2015,11(2):225-238.
16 Xu H,Zeng S,Wang Y,et al.Cytoplasmic SIRT1 promotes paclitaxel resistance in ovarian carcinoma through increased formation and survival of polyploid giant cancer cells[J].J Pathol,2023,261(2):210-226.
17 Wu X,Zhao J,Ruan Y,et al.Sialyltransferase ST3GAL1 promotes cell migration,invasion,and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer[J].Cell Death Dis,2018,9(11):1102.
18 Yu Z,Wang Y,Wang B,et al.Metformin affects paclitaxel sensitivity of ovarian cancer cells through autophagy mediated by long noncoding RNASNHG7/miR-3127-5p axis[J].Cancer Biother Radiopharm,2022,37(9):792-801.
19 Kim JS,Shin MJ,Lee SY,et al.BBT-877,a novel autotaxin inhibitor,abrogates drug resistance in epithelial ovarian cancer stem cells[J].Anticancer Res,2024,44(3):1131-1142.
20 Lacroix A,Farhat R,Robert A,et al.The first-in-class pro-apoptotic peptide PEP-010 is effective in monotherapy and in combination with paclitaxel on resistant ovarian adenocarcinoma cell models[J].Front Pharmacol,2024,15:1444973.
21 Kong QW,Yang J,Li D,et al.Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo[J].J Ethnopharmacol,2023,300:115728.
22 Huang SL,Chang TC,Sun NK.Curcumin reduces paclitaxel resistance in ovarian carcinoma cells by upregulating SNIP1 and inhibiting NFκB activity[J].Biochem Pharmacol,2023,212:115581.
23 Yang J,Li N,Zhao X,et al.WP1066,a small molecule inhibitor of STAT3,chemosensitizes paclitaxel-resistant ovarian cancer cells to paclitaxel by simultaneously inhibiting the activity of STAT3 and the interaction of STAT3 with Stathmin[J].Biochem Pharmacol,2024,221:116040.
24 Moisan F,Francisco EB,Brozovic A,et al.Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers[J].Mol Oncol,2014,8(7):1231-1239.
25 Li X,Guan W,Liu H,et al.Targeting PNPO to suppress tumor growth via inhibiting autophagic flux and to reverse paclitaxel resistance in ovarian cancer[J].Apoptosis,2024,29(9-10):1546-1563.
26 Lim YJ,Kim HS,Bae S,et al.Pan-EGFR inhibitor dacomitinib resensitizes paclitaxel and induces apoptosis via elevating intracellular ROS levels in ovarian cancer SKOV3-TR cells[J].Molecules,2024,29(1):274.
27 Bae S,Bae S,Kim HS,et al.Deguelin restores paclitaxel sensitivity in paclitaxel-resistant ovarian cancer cells via inhibition of the EGFR signaling pathway[J].Cancer Manag Res,2024,16:507-525.
28 Wu D,Liu J,Yang X,et al.ANGPTL3 diminishes the resistance of ovarian cancer to paclitaxel by blocking the PI3K-Akt-mTOR signaling pathway[J].Heliyon,2024,10(11):e31520.
29 Gelderblom H,Verweij J,Nooter K,et al.Cremophor EL:the drawbacks and advantages of vehicle selection for drug formulation[J].Eur J Cancer,2001,37(13):1590-1598.
30 Wu Y,Yang Y,Lv X,et al.Nanoparticle-based combination therapy for ovarian cancer[J].Int J Nanomedicine,2023,18:1965-1987.
31 Wang L,Li S,Zhu D,et al.Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer:a retrospective study[J].J Gynecol Oncol,2023,34(4):e44.
32 Cheng C,Jiang W,Luo Y,et al.NIR activated multimodal therapeutics based on metal-phenolic networks-functionalized nanoplatform for combating against multidrug resistance and metastasis[J].Small,2023,19(14):e2206174.
33 Korzun T,Moses AS,Kim J,et al.Nanoparticle-based follistatin messenger RNA therapy for reprogramming metastatic ovarian cancer and ameliorating cancer-associated cachexia[J].Small,2022,18(44):e2204436.
34 Lai MH,Lin WJ.Zein-PEG nanoparticles modified with hyaluronic acid for paclitaxel delivery in SKOV3 ovarian cancer cells[J].Int J Biol Macromol,2024,281(Pt 4):136651.
35 Gaikwad NM,Chaudhari PD,Shaikh KS,et al.Dual drug-loaded polymeric mixed micelles for ovarian cancer:Approach to enhanced therapeutic efficacy of albendazole and paclitaxel[J].J Cell Mol Med,2024,28(11):e18389.

[1]	SU Shaofei, ZHANG Enjie, LIU Jianhui, GAO Yan. Exploring the causal relationship between 20 metabolites and ovarian cancer risk based on Mendelian randomization [J]. Journal of Practical Oncology, 2025, 39(3): 191-200.
[2]	WU Xu, DE Leheibateer, DA Lintai, SU Nite, LIU Jun. Research progress of long non-coding RNA in oral squamous cell carcinoma [J]. Journal of Practical Oncology, 2025, 39(3): 251-255.
[3]	WANG Rui, MA Deyuan, JIA Wangqiang, GUAN Quanlin. Application and progress of nano-medicine mediated cuproptosis in the breast cancer treatment [J]. Journal of Practical Oncology, 2025, 39(2): 144-150.
[4]	KOU Shuai, WANG Yuping, SUN Xiaoxia, REN Juanjuan. Analysis of incidence and mortality of ovarian cancer in China from 1992 to 2021 based on age-period-cohort model [J]. Journal of Practical Oncology, 2025, 39(1): 7-12.
[5]	ZHANG Hua, Nurbia Ibibulla, LU Pengfei, JIA Chunli, PEI Xuanxuan, BAO Yongxing. Effect and mechanism of CXCL8 on the paclitaxel sensitivity of cervical cancer cells [J]. Journal of Practical Oncology, 2025, 39(1): 13-20.
[6]	HAN Jing, GUAN Quanlin. Research progress of tumor-associated neutrophils in immune checkpoint inhibitors resistance [J]. Journal of Practical Oncology, 2024, 38(5): 349-354.
[7]	SUN Lijun, DONG Dawei. Classification and prognosis of ovarian cancer based on platinum resistance related genes [J]. Journal of Practical Oncology, 2024, 38(3): 184-191.
[8]	GAO Yan, HAN Xiaoyang, CHENG Jin, HOU Lisha, YUE Wentao. Single cell sequencing data reveal PHLDA1 as a critical molecule responsible for T cell exhaustion in ovarian cancer [J]. Journal of Practical Oncology, 2024, 38(2): 79-87.
[9]	SHANG Hongyue, YAO Manman, LU Yueting, WANG Dixian, ZHAO Qian, LIU Tiejun. Research progress of long non-coding RNA CASC2 in tumor chemotherapy resistance [J]. Journal of Practical Oncology, 2024, 38(1): 67-70.
[10]	GAO Yan, YAO Mengcheng, LI Zhefeng, HAN Xiaoyang, YUE Wentao. Single cell sequencing data reveal the diagnostic and predictive value of DMKN in ovarian cancer [J]. Journal of Practical Oncology, 2023, 37(6): 478-484.
[11]	CAO Xinyu, ZHOU Xu, WANG Quan, JIANG Wei. Potential mechanisms and prediction methods of anticancer drug resistance [J]. Journal of Practical Oncology, 2023, 37(6): 491-495.
[12]	FAN Tingting, DING Danni, ZHAO Zixue, YU Yang, HAN Fengjuan. Fatty acid metabolism and ovarian cancer [J]. Journal of Practical Oncology, 2023, 37(5): 429-433.
[13]	ZHANG Yan, TIAN Suli, ZHOU Yongxu, LIU Chang. Regulating mechanism of miR-7 in sensitivity of colorectal cancer cells to 5-fluorouracil [J]. Journal of Practical Oncology, 2023, 37(4): 320-328.
[14]	FENG Chengtian, HUANG Furong, JIANG Yongdong. Research progress of lipid metabolism on the mechanism of drug resistance to trastuzumab therapy in breast cancer [J]. Journal of Practical Oncology, 2023, 37(2): 155-159.
[15]	LI Zhihui, LI Zhigao. Research progress of T-DM1 in treatment of HER2 positive breast cancer [J]. Journal of Practical Oncology, 2022, 36(5): 477-482.

Research progress on paclitaxel resistance in ovarian cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments